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Abstract
Introduction: Neutrophil recovery has been implicated in deterioration of oxygenation and exacerbation of
preexisting acute lung injury (ALI). The aim of this study was to investigate whether imatinib or nilotinib was
effective on lipopolysaccharide (LPS)-induced ALI during neutropenia recovery in mice.
Methods: Mice were rendered neutropenic with cyclophosphamide prior to the intratracheal instillation of LPS.
Imatinib or nilotinib was administrated by oral gavage during neutropenia recovery. In order to study the effects of
drugs, mice were killed on day 5 and blood, bronchoalveolar lavage (BAL) fluid and lung tissue samples were
obtained. The lung wet/dry weight ratio and protein levels in the BAL fluid or lung tissue were determined.
Results: Treatment with imatinib or nilotinib significantly attenuated the LPS-induced pulmonary edema, and this
result was supported by the histopathological examination. The concentrations of tumor necrosis factor-a,
interleukin (IL)-1b, IL-6 and myeloperoxidase in BAL fluid were significantly inhibited by imatinib or nilotinib in mice
of ALI during neutropenia recovery. The mRNA expressions of platelet-derived growth factor receptor-b and c-KIT
in imatinib or nilotinib group were significantly lower than LPS group.
Conclusions: Our data indicated that imatinib or nilotinib effectively attenuated LPS-induced ALI during
neutropenia recovery. These results provide evidence for the therapeutic potential of imatinib and nilotinib in ALI
during neutropenia recovery.
Keywords: Acute lung injury, neutropenia recovery, imatinib, nilotinib, platelet-derived growth factor receptor
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Introduction
Acute lung injury (ALI) and acute respiratory failure are the
major cause of morbidity and the major reason for ICU
admission in cancer patients [1-4]. Neutropenia, character-
ized by low count of neutrophils, which have a critical role
in the pathophysiology of acute respiratory distress syn-
drome (ARDS) and ALI, is mostly a commonly expected
event in the numerous cancer patients who are adminis-
tered chemotherapy [5,6]. Neutropenia recovery may be
related to an increased risk of deteriorating oxygenation
and may exacerbate pre-existing ALI associated with infec-
tious or noninfectious causes [7-11].
Most clinical studies have focused on the significant role
of ALI before neutropenia recovery to detect confounding
factors affecting the recovery. However, experimental stu-
dies to prevent or attenuate factors for ALI/ARDS after
neutropenia recovery have been lacking to date, although
ARDS has been widely reported during neutropenia
recovery.
Lipopolysaccharide (LPS), a component of gram-negative
bacterial endotoxin, is recognized as the main component
causing ALI. It has been shown that ALI due to LPS instil-
lation results in an increase in the numbers of total cells
and neutrophils, as well as various proimflammatory cyto-
kines such as TNF-a, IL-1b and IL-6 in bronchoalveolar
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lavage (BAL) fluid, and increased protein leakage, pulmon-
ary elastance and resistance. There is also recent clinical
evidence that increased TNF-a, IL-1b and IL-6 levels are
associated with poor patient outcome in ALI.
Imatinib and nilotinib (Novartis Pharmaceuticals) are
protein tyrosine kinase inhibitors whose main targets
include platelet-derived growth factor (PDGF) receptor
(PDGFR), discoidin domain receptor, stem cell factor
receptor (KIT), Abelson kinase (ABL) and the oncogenic
breakpoint cluster region-Abelson kinase (BCR-ABL) that
causes chronic myeloid leukemia [12]. Imatinib and its
advancer, nilotinib, have been shown to possess other ben-
eficial pharmacological effects such as anti-inflammatory
activities and antifibrotic effects [13,14]. There is evidence
that these agents specifically attenuate airway hyper-reac-
tivity [15] and its ability to inhibit PDGFR tyrosine kinase
[14]. In a recent case report, PDGF has been known to
play a key role in acute lung injury [16]. However, whether
imatinib and nilotinib could affect ALI during neutropenia
recovery and ultimately improve the ALI is unknown.
We hypothesized that imatinib and nilotinib may inhibit
the cytokine production involved in the development of
ALI. Therefore, the aim of the present study was to evalu-
ate whether imatinib or nilotinib was effective in LPS-
induced ALI during neutropenia recovery in a mouse




Female 5-week-old ICR mice, weighing 18 to 22 g (n = 10
per group), were purchased from Orient Bio Experimental
Animal Center, Kyoungki, Korea. All animals were main-
tained in a pathogen-free environment and had access to
food and water ad libitum. Mice were randomly allocated
into four groups: (i) control; (ii) cyclophosphamide + LPS
(2 μg/g, Sigma, St. Louis, MO, USA); (iii) cyclophospha-
mide + LPS + imatinib (100 mg/kg, twice a day); and (iv)
cyclophosphamide + LPS + nilotinib (100 mg/kg, once a
day). Neutropenia was induced in the animals by intraperi-
toneal injections of cyclophosphamide of 150 mg/kg on
day -5 (before imatinib or nilotinib administration) and
100 mg/kg on day -2. Imatinib or nilotinib (provided by
Novartis Pharmaceuticals, Basel, Switzerland) was admi-
nistered by oral gavage on day 0 and continued until
euthanasia. In the groups (ii), (iii), and (iv), mice were
given LPS (2 μg/g) through intratracheal instillation on
day 2. Mice were sacrificed on day 5.
We also performed two additional experiments. First,
we added two groups (LPS and saline) and compared the
degree of lung injury. In the LPS group, mice was given
LPS (2 μg/g) through intratracheal instillation without
treatment of cyclophosphamide. Instead of LPS, the sal-
ine group received the same amount of saline through
intratracheal instillation without cyclophosphamide treat-
ment. Second, we gave imatinib or nilotinib after, instead
of before, LPS administration. We compared the effect of
imatinib or nilotinib in the pre- and post-LPS groups.
The experiments were approved by the ethical com-
mittee on animal experiments of The Catholic Univer-
sity of Korea.
Quantification of lung wet/dry weight ratio
Mice were sacrificed by CO2 asphyxiation. At the com-
pletion of the experiment, the upper lobe of the right
lung was excised and immediately weighed to determine
the wet/dry (W/D) weight ratio. It was then dried at 60°C
for 72 hrs, and reweighed. The ratio of W/D weight was
used to quantify lung water content [17].
Lung histopathology
After sacrifice, the lungs were inflated, fixed in 4% parafor-
maldehyde for 24 hrs, and then embedded in paraffin wax.
Sections were cut at 4-μm thickness using a microtome,
and stained with H&E using standard techniques for histo-
logical changes.
Bronchoalveolar lavage
The trachea was cannulated with a small catheter, and
BAL fluid was collected by washing the lungs with 0.8 ml
of ice-cold sterile PBS. Total cell counts in BAL fluid were
measured using a hemocytometer. Total leukocyte counts
were obtained by light microscopic evaluation and the per-
centages of BAL fluid macrophages, neutrophils, eosino-
phils and lymphocytes were obtained by counting 500
leukocytes on randomly selected portions. BAL fluid was
analyzed by cytospin stained with Diff Quik (Sysmax,
Tokyo, Japan). The supernatant of BAL fluid was aliquoted
and frozen at -80°C until further analysis.
Myeloperoxidase activity assay
Myeloperoxidase (MPO) concentration in BAL fluid was
determined using the Mouse MPO ELISA kit (Uscn Life
Science, Wuhan, China) according to the manufacturer’s
instructions. Briefly, BAL fluid was centrifuged at 13,000
rpm for 10 minutes at 4°C and the supernatant discarded.
The leukocyte pellet was suspended again in extraction
buffer. The sensitivity of the assay was 0.78 ng/ml. Opti-
cal density was measured at 450 nm by use of a micro-
plate reader.
Enzyme-linked immunosorbent assay
The concentrations of TNF-a, IL-6 and IL-1b in BAL
fluids were measured using an ELISA kit (R&D Systems,
Minneapolis, MN, USA). The sensitivities of the assay
were 15.6 pg/ml, 3 pg/ml and 7 pg/ml, respectively. The
protocol was performed according to the manufacturer’s
instructions.
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Western blot
Separated lung tissues were homogenized in radio immu-
noprecipitation assay (RIPA) cell lysis buffer (150 mM
NaCl, 1% triton X-100, 1% sodium deoxycholate, 0.1%
SDS, 50 mM Tris-HCl, pH 7.5, and 2 mM ethylenediami-
netetraacetic acid (EDTA)) containing a mixture of pro-
tease inhibitors (GenDEPOT, CA, USA) and then
centrifuged at 13,000 rpm for 15 minutes at 4°C, followed
by collection and storage of supernatant at -80°C. Protein
samples were separated by 8% sodium dodecyl sulfate
polyacrylamide gel electrophoresis and transferred to
Immobilon-P (Millipore) polyvinylidene difluoride mem-
branes. The membrane was blocked with 5% skimmed
milk (Difco/Becton Dickinson, Atlanta, GA, USA) for
2 hrs at room temperature, followed by incubation with a
1:200 dilution of anti-PDGFR-b (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) or a 1:1,000 dilution anti-p-
PDGFR-b antibody (Cell Signaling, Danvers, MA, USA)
overnight at 4°C. After incubation, the blot was washed
with Tris-buffered saline containing 0.1 % Tween 20
(TBS-T) for 30 minutes and incubated with a 1:2,000 dilu-
tion of goat anti-rabbit secondary antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) for 2 hrs at room
temperature. The blot was then washed with TBS-T for
1 hr, developed using the ECL Western Blotting Analysis
System, and exposed to film.
Real-time polymerase chain reaction
Total RNA was extracted from lung tissue using the TRI-
zol reagent™ (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s recommendations. After extraction
and quantification of total RNA, real-time PCR reactions
were performed using a QuantiTect SYBR Green RT-PCR
kit (Qiagen, Valencia, CA, USA). Each PCR was carried
out in a final volume of 25 μl (100 ng cDNA, 1 μmol/l of
primers, 2× SYBR RT-PCR Master Mix, RNase-free
water). The PCR conditions were 95°C (10 minutes), fol-
lowed by 40 cycles at 95°C (15 sec), 60°C (1 minute), and
the standard denaturation curve. Primer sequences used
were: PDGFR-b [NCBI:NM001146268.1], forward 5’-
TGGGCTTCAGCTACCAAGTG-3’, reverse 5’- AAGG
TGCTGCCTTTGGAGAT-3’; b-actin (housekeeping con-
trol, [NCBI:NM007393.3]), forward 5’-ACAGGAAGTC
CCTTGCCATC-3’, reverse 5’-AGGGAGACCAAAAGC
CTTCA-3’. Gene expression was quantified using standard
curves for the respective cDNA products. To normalize
the content of cDNA samples, the comparative threshold
(CT) cycle method, consisting of the normalization of the
number of target gene copies versus the housekeeping
gene b-actin, was used. The changes in target signal were
expressed as:
CT = CT,treatment −CT,control
Relative changes were calculated as 2-ΔΔCT.
Statistical analysis
The data were analyzed by one-way analysis of variance
(ANOVA) followed by Dunnett’s multiple range test,
using Graph-Pad Prism version 5.00 for Windows
(GraphPad Software, San Diego, CA, USA). All data are
expressed as means ± SD, and a P-value <0.05 was
accepted as statistically significant. SPSS for Windows
was used for the statistical tests.
Results
Effect of cyclophosphamide on neutrophils
The cytotoxic effect of cyclophosphamide in mice was
monitored by neutrophil counts. In mice given cyclo-
phosphamide, neutrophils in the peripheral blood
reached a minimum at day 1 and recovered at day 5
(Figure 1).
Effect of imatinib or nilotinib on lung histopathology
To evaluate the effect of imatinib or nilotinib in the his-
topathological changes in the lung in LPS-induced ALI,
lung tissues were assessed after the administration of
LPS during neutropenia recovery with or without treat-
ment. We observed marked acute alveolar damage,
acute inflammation and interstitial edema in LPS-
induced ALI during neutropenia recovery (Figure 2B),
compared with the control group (Figure 2A). In the
group pretreated with imatinib or nilotinib before LPS,
administration of drugs effectively reduced the inflam-
matory changes in the lung (Figure 2C and 2D).
Effect of imatinib or nilotinib on pulmonary edema
Pulmonary edema formation, indicative of pulmonary vas-
cular leakage, happens with an increase in the lung W/D
ratio. To investigate the effect of imatinib or nilotinib on
LPS-induced lung edema, the lung W/D ratios and the
concentration of albumin in BAL fluids were measured.
As shown in Figure 3A, we found that there was an
obvious increase in W/D ratio in the group that had LPS
administration during neutropenia recovery, compared
with the control group. However, administration of imati-
nib or nilotinib prior to LPS significantly reduced the lung
W/D ratios. The level of albumin in BAL fluid was
increased in mice challenged with LPS during neutropenia
recovery compared with control mice, whereas treatment
with imatinib or nilotinib prior to LPS significantly attenu-
ated the albumin level (Figure 3B).
Effect of imatinib or nilotinib on inflammatory cells
To investigate the protective effect of imatinib or niloti-
nib on LPS-induced ALI during neutropenia recovery,
we detected the total inflammatory cell counts in BAL
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fluid from mice treated with LPS with or without imati-
nib or nilotinib. As shown in table 1, inflammatory cells
and neutrophils in the BAL fluid were significantly
increased after administration of LPS during neutrope-
nia recovery (P <0.01), whereas we observed that admin-
istration of imatinib or nilotinib significantly reduced
the number of total cells and neutrophils compared
with the LPS group (P <0.01).
Effect of imatinib or nilotinib on inflammatory cytokines
and MPO
To assess the anti-inflammatory effect of imatinib or
nilotinib, we analyzed the proinflammatory cytokines,
including TNF-a, IL-6, IL-1ß, and MPO in BAL fluid.
We found that the concentrations of TNF-a, IL-6, IL-
1ß, and MPO were dramatically increased in BAL fluid
after LPS administration during neutropenia recovery.
The concentrations of TNF-a, IL-6 and IL-1ß in
response to LPS were 812.16 ± 84.88 pg/ml, 394.19 ±
67.00 pg/ml and 1,476.81 ± 268.95 pg/ml, respectively,
indicating approximately 58.2-, 109.0- and 8.8-fold
increases compared with control group. In contrast,
administration of imatinib or nilotinib after LPS chal-
lenge effectively decreased the levels of TNF-a, IL-6, IL-
1ß and MPO (Figure 4).
Effect of imatinib or nilotinib on activation of PDGFR-ß
Western blot analysis of the phosphorylation of PDGFR-
ß revealed significant upregulation in the group with
LPS during neutropenia recovery, whereas the group
treated with imatinib or nilotinib there was a reduction
toward control levels (Figure 5). There was no signifi-
cant difference in the expression of non-phosphorylated
PDGFR-ß in mice exposed to LPS during neutropenia
recovery compared with the control group.
Effect of imatinib or nilotinib on mRNA expression of
PDGFR-ß
Real-time PCR was used to analyze the effect of imatinib
or nilotinib on the mRNA expression of PDGFR-ß in
Figure 1 Effect of cyclophosphamide in mice. All mice received 150 mg/kg cyclophosphamide by intraperitoneal injection on day (D) -5
before they became neutropenic and 100 mg/kg on day -2 before administration of imatinib or nilotinib. Neutrophils were measured in the
peripheral blood every day to monitor the cytotoxic effect of cyclophosphamide until mice were sacrificed. WBC, white blood cell.
Figure 2 Effect of imatinib or nilotinib on the histopathological changes in the lung in mice lipopolysaccharide-induced acute lung
inury. Representative images of H&E-stained lung sections from four experimental groups: (A) control group; the lung structure is normal, (B)
cyclophosphamide (C) + lipopolysaccharide (LPS) group; LPS induced acute lung damage with interstitial edema, hemorrhage, thickening of the
alveolar wall and infiltration of inflammatory cells into the interstitium and alveolar spaces, (C) C + LPS + imatinib (I) group, (D) C + LPS +
nilotinib (N) group; lung injury was attenuated by treatment with imatinib or nilotinib.
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lung tissue after the LPS challenge. As shown in Figure
6, the administration of LPS during neutropenia recov-
ery induced a significant increase in the mRNA expres-
sion of PDGFR-ß as compared to the control group.
Imatinib or nilotinib significantly reduced LPS-induced
PDGFR-ß expression (Figure 6, P <0.01).
Comparison of degree of lung injury
We compared the degree of lung injury in the LPS
group and the cyclophosphamide + LPS group. We also
compared the control and the saline group. In the histo-
pathology, there was little inflammation in the control
or the saline group. Acute lung damage with interstitial
edema, hemorrhage, thickening of the alveolar wall and
infiltration of inflammatory cells into the interstitium
and alveolar spaces were observed in both the LPS and
the cyclophosphamide + LPS group (Figure 7A). In BAL
cell count analysis, there was a significant difference
between the control and the saline group in the number
of total cells (P <0.05). However, the neutrophil count
did not differ significantly between the control and the
saline group. There was also significant difference
between the LPS group and the cyclophosphamide +
LPS group in the number of total cells (P <0.01).
However, the neutrophil count did not differ signifi-
cantly in the LPS group and the cyclophosphamide +
LPS group (Figure 7B). In the analysis of MPO, there
was no significant difference between the control and
the saline group. There was also no significant differ-
ence between the LPS group and the cyclophosphamide
+ LPS group (Figure 7C).
Post-treatment effect of imatinib or nilotinib
In the histopathology, imatinib or nilotinib given pre- or
post-induction of lung injury attenuated lung injury com-
pared with cyclophosphamide + LPS (Figure 8A). Com-
pared with the cyclophosphamide + LPS group, the total
cell count did not differ significantly in the group that
received imatinib post treatment. However, the neutrophil
count differed significantly in the group receiving imatinib
post treatment (P <0.05). Compared with cyclophospha-
mide + LPS group, both total cell and neutrophil count
were significantly lower in post-treatment of nilotinib
group (P <0.01). The total cell and neutrophil counts were
significantly higher in post-treatment imatinib group com-
pared with the pre-treatment group (P <0.01). However,
there was no significant difference between the pre- and
post-treatment nilotinib group in the numbers of total
Figure 3 Effect of imatinib or nilotinib on lung edema in mice with lipoplysaccharide-induced acute lung injury. After lipopolysaccharide
(LPS) administration, treatment with imatinib or nilotinib markedly decreased (A) lung wet/dry (W/D) weight ratio and (B) albumin. The lower
lobe of the right lung was removed and weighed (wet weight), dried at 60°C for 72 hrs, and weighed again (dry weight). The W/D ratio was
used as an indicator of lung edema formation. C, cyclophosphamide; I, imatinib; N, nilotinib. Asterisks indicates significant differences to the C +
LPS group (*P <0.05, **P <0.01).
Table 1 Results of bronchiolar lavage fluid analysis (104/ml) in the four groups
Control C + LPS C + LPS + I C + LPS + N
Total cells 6.00 ± 2.35 80.60 ± 16.30** 36.20 ± 7.26## 43.40 ± 6.91##
Macrophages 3.67 ± 2.15 4.18 ± 0.68 5.63 ± 3.20 3.49 ± 4.88
Lymphocytes 0.00 ± 0.00 0.34 ± 0.56 0.00 ± 0.00 0.00 ± 0.00
Neutrophils 0.00 ± 0.00 71.46 ± 16.09** 26.38 ± 2.85## 14.46 ± 20.24##
Eosinophils 0.34 ± 0.21 4.64 ± 3.95 4.20 ± 4.81 2.04 ± 2.83
Results are presented as mean ± SD. LPS, lipopolysaccharide; C, cyclophosphamide; I, imatinib; N, nilotinib. **P <0.01 for control versus C + LPS; ##P <0.01 for C +
LPS versus C + LPS + I or N.
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cells and neutrophils (Figure 8B). Compared with the
cyclophosphamide + LPS group, the albumin level was sig-
nificantly lower in the imatinib and nilotinib post-treat-
ment groups (P < 0.01). Compared with imatinib and
nilotinib post-treatment groups, the albumin level was
also significantly lower in the imatinib and nilotinib pre-
treatment groups (Figure 8C, P <0.01). Compared with the
cyclophosphamide + LPS group, MPO was significantly
lower in the imatinib and nilotinib post-treatment groups
(P < 0.05). There was no significant difference in MPO
between the imatinib or nilotinib pre- and post-treatment
groups (Figure 8D).
Figure 4 Effect of imatinib or nilotinib on the protein level of inflammatory cytokines and myeloperoxidase in mice with
lipoplysaccharide-induced acute lung injury. The levels of (A) TNF-a, (B) IL-6, (C) IL-1b and (D) myeloperoxidase (MPO) were assayed in
bronchiolar lavage (BAL) fluid and the sensitivities of the assay were 15.6 pg/ml, 3 pg/ml, 7 pg/ml and 0.78 ng/ml, respectively. Intratracheal
administration of lipopolysaccharide (LPS) induced increased levels of TNF- a, IL-6, IL-1b and MPO. Compared with the cyclophosphamide (C) +
LPS group, the level of inflammatory cytokines and MPO was significantly lower in the imatinib or nilotinib group. I, imatinib; N, nilotinib.
Asterisks indicates significant differences to the C + LPS group (*P <0.05, **P <0.01).
Figure 5 Effect of imatinib or nilotinib on activation of p-platelet-derived growth factor receptor-ß in mice with lipoplysaccharide-
induced acute lung injury. Lung tissues were homogenized and the extracted protein samples were separated by SDS-PAGE using 8% PAGE
gel, followed by transfer to 0.45 μm polyvinylidene fluoride membranes. The membranes were blocked with 5% skimmed milk and exposed
overnight at 4°C to specific anti-platelet-derived growth factor receptor-ß (PDGFR-b) and anti-phospho-PDGFR-b antibodies. LPS,
lipopolysaccharide; C, cyclophosphamide; I, imatinib; N, nilotinib.
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Discussion
In this study, we observed the pretreatment effect of
imatinib and nilotinib in LPS-induced lung injury in the
neutropenic mouse model. Although many cases of
ALI/ARDS during neutropenia recovery have been
reported [18], risk factors or marked therapeutic agents
in patients experiencing neutropenia recovery have not
previously been studied.
Chemotherapy is administered to the majority of can-
cer patients, with neutropenia being a frequent adverse
event. In patients, pulmonary infiltrates develop during
neutropenia and considerably worsen upon neutropenia
Figure 6 Effect of imatinib or nilotinib treatment on mRNA expression of platelet-derived growth factor receptor in mice with
lipoplysaccharide-induced acute lung injury. The mRNA expression of platelet-derived growth factor receptor-ß (PDGFR) was measured in
lung tissues. In real-time PCR analysis, to normalize the content of cDNA samples, the comparative threshold (CT) cycle method, consisting of
the normalization of the number of target gene copies versus the housekeeping gene b-actin, was used. LPS, lipopolysaccharide; C,
cyclophosphamide; I, imatinib; N, nilotinib. Asterisks indicate significant differences from the C + LPS group (**P < 0.01).
Figure 7 Comparison of degree of lung injury. (A) Representative images of H&E-stained lung sections from four experimental groups. (B)
Number of inflammatory cells in bronchoalveolar lavage (BAL) fluid. (C) Result of myeloperoxidase (MPO) analysis. LPS, lipopolysaccharide; C,
cyclophosphamide; I, imatinib; N, nilotinib. *P <0.05; **P <0.01; NS, non-significant.
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recovery [10]. A few case reports have been published
showing that neutropenia recovery carries a risk of
acute respiratory failure such as ALI and ARDS [19,20].
Azoulay et al. [20] showed that cancer patients recover-
ing from neutropenia were frequently admitted for acute
respiratory failure and that one third of patients experi-
enced ARDS during neutropenia recovery. During neu-
tropenia recovery, the accumulation of activated
neutrophils in the pulmonary vasculature generally
occurred [6]. Activated neutrophils that quickly accumu-
late in the pulmonary parenchyma following endotoxin
administration [21] or hypovolemic shock [22] have a
major role in the development of inflammatory response
in ALI [23]. Inflammatory cells, including neutrophils
and lymphocytes, in BAL fluid have a principal role in
the pathogenesis of ALI [24].
PDGF, one of the growth factors whose receptors are
targeted by imatinib and nilotinib, plays a key role in
the pathogenesis of lung diseases including pulmonary
fibrosis, ALI and ARDS [17,25]. PDGF is a chemotactic
factor for monocytes and granulocytes during inflamma-
tion and overexpression of PDGF can induce inflamma-
tory injury [26]. Previous studies suggest that PDGF
may be an important factor in ALI. Snyder et al. [27]
showed that the concentration of PDGF is significantly
higher in patients with ALI than in normal or control
patients. Budinger et al. [28] showed that there was a
significant negative correlation between active TGF-b1
(stimulator of PDGF) levels and ventilator-free days and
ICU-free days. In addition to these clinical data, Walsh
et al. [29] showed that PDGF plays a crucial role in the
tissue repair processes of bleomycin-induced lung injury
in a rat model and leads to fibroblast proliferation and
chemotaxis. There are also many reports that on PDGF
as a therapeutic target in ALI. In a previous study, we
showed that imatinib and nilotinib attenuated bleomy-
cin-induced ALI by blocking the PDGF pathway [30].
Zhao et al. [31] observed therapeutic effects of bone
Figure 8 Effect of post-treatment with imatinib or nilotinib. (A) Representative images of H&E-stained lung sections from six experimental
groups. (B) Number of inflammatory cells in bronchoalveolar lavage (BAL) fluid. (C) Albumin level in BAL fluid. (D) Myeloperoxidase (MPO)
analysis. LPS, lipopolysaccharide; C, cyclophosphamide; I, imatinib; N, nilotinib. *P <0.05 and **P <0.01 for C + LPS versus C + LPS + I/N (post);
#P <0.05 and ##P <0.01 for C + LPS + I/N versus C + LPS + I/N (post). Post, post-induction of LPS.
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marrow-derived mesenchymal stem cells in lung injury
and this effect was accompanied by a decreased in
PDGF. Yi and colleagues [32] showed that keratinocyte
growth factor can attenuate bleomycin-induced lung
injury by decreasing the expression of PDGF.
Recent evidence showed that imatinib and nilotinib
have various effects in airway hyper-reactivity and
inflammatory responses [30,33-35] as they specifically
inhibit PDGFR tyrosine kinase [14,16,17]. In this study,
we found that treatment of imatinib or nilotinib signifi-
cantly decreased the phosphorylation of PDGFR-ß. We
also confirmed that imatinib or nilotinib could decrease
the mRNA expression of PDGFR-ß. These previous
reports together with our results suggest that inhibition
of PDGF/PDGFR may be a potential approach to pre-
vent lung injury.
We have observed that imatinib and nilotinib have an
anti-inflammatory effect. This beneficial effect could
contribute to attenuation of lung injury. In BAL fluid
analysis, total cells and neutrophils in the BAL fluid
were significantly decreased by treatment with imatinib
or nilotinib in mice with LPS-induced ALI during neu-
tropenia recovery. Similarly, MPO activity, which indi-
cates neutrophil and macrophage leakage, was
significantly increased in BAL fluid after the administra-
tion of LPS. These results confirm that a potent protec-
tive effect of imatinib or nilotinib on LPS-induced ALI
during neutropenia recovery is related to an attenuation
of lung inflammation and tissue neutrophilia. The anti-
inflammatory effect of imatinib and nilotinib is consis-
tent with previous reports. Miyachi et al. [36] and
Eklund et al. [37,38] reported that imatinib has an anti-
inflammatory effect and this drug can be used for the
treatment of rheumatoid arthritis. In animal studies pre-
vious experiments consistently showed that imatinib and
nilotinib decreased total cells and/or neutrophils in BAL
fluid [15,30,33].
It has been shown that the early release of several
inflammatory and chemotactic cytokines, such as TNF-
a, IL-6 and IL-1ß, enlarge and facilitate inflammatory
responses in ALI [39,40]. These are the primary multi-
functional cytokines produced from inflammatory cells
that exacerbate the extent of lung injury [41]. As in pre-
vious studies [42,43], our results showed that the
expressions of TNF-a, IL-6 and IL-1ß were significantly
increased in BAL fluid after LPS administration as com-
pared to control group, whereas administration of imati-
nib or nilotinib significantly downregulated the
expression of these cytokines as compared to the LPS
group.
Conclusions
In the present study, we found that administration of
imatinib or nilotinib effectively attenuated the LPS-
induced ALI during neutropenia recovery in mice.
These effects of imatinib or nilotinib were associated
with the inhibition of infiltration of inflammatory cells
into the lung and reduction of the activation of inflam-
matory cytokines. Moreover, the beneficial effects of
imatinib and nilotinib were closely connected with inhi-
bition of the PDGF pathways, because the PDGF signal-
ing pathway has been involved in developing organ
fibrosis and inflammation [44]. However, the accurate
intracellular mechanism of the effects of imatinib and
nilotinib in mice with LPS-induced ALI still remains to
be elucidated. Furthermore, it is necessary to confirm
these results in more clinically relevant models.
Key messages
• Pretreatment with imatinib or nilotinib before LPS
exposure during neutropenia recovery, effectively pre-
vented the degree of pulmonary edema and reduced the
inflammatory changes in lung tissues.
• Administration of imatinib or nilotinib before instil-
lation of LPS during neutropenia recovery significantly
downregulated several inflammatory and chemotactic
cytokines, such as TNF-a, IL-6 and IL-1ß.
• Pretreatment with imatinib or nilotinib before instil-
lation of LPS during neutropenia recovery, significantly
decreased the phosphorylation of PDGFR-ß as well as
the mRNA expression.
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